Daniel O. Persky MD
Assistant Professor of Medicine (Hematology)
Clinical trials, lymphoma, translational research, diffuse large B-cell lymphoma
My clinical focus as a medical oncologist is on B-cell lymphoid malignancies and my major research interest is using disease biology to guide therapeutic development. In particular, my focus is on diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. I am a member of SWOG Lymphoma Committee and serve as a Principal Investigator on two national clinical trials in this type of lymphoma.
- Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, and Miller TP. Effect of Adding Rituximab to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Patients with Limited Stage Aggressive B-Cell Lymphoma. A Southwest Oncology Group Study 0014. J Clin Oncol 2008 May 10;26(14):2258-63. Epub 2008 Apr 14.
- Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin embedded tissues of diffuse large B cell lymphoma treated with R-CHOP. Blood 2008 Oct 15; 112(8):3425-33. Epub 2008 Jun 10.
- Persky DO, Moskowitz, CH, Filatov A, Saxena R, Haiyan C, Teruya-Feldstein. J. High dose Chemoradiotherapy and ASCT May Overcome the Prognostic Importance of Biologic Markers in Relapsed/Refractory Hodgkin’s Lymphoma. Appl Immunohistochem Mol Morphol 2010 Jan;18(1):35-40.
- Persky DO, Dornan D, Goldman B, Braziel R, Fisher R, Leblanc M. Maloney DG, Press O, Miller T, Rimsza LM. Fc Gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012 Jan 22 [Epub ahead of print] PMID 22271896